Have a personal or library account? Click to login
Sanguinarine Inhibits Cell Growth in EBV-Positive Diffuse Large B-Cell Lymphoma Cover

Sanguinarine Inhibits Cell Growth in EBV-Positive Diffuse Large B-Cell Lymphoma

By: Suli Lu and  Dae-jung Yang  
Open Access
|Apr 2025

References

  1. Alakkal A, Thayyullathil F, Pallichankandy S et al. (2022) Sanguinarine induces h(2)o(2)-dependent apoptosis and ferroptosis in human cervical cancer. Biomedicines 10:1795. https://doi.org/10.3390/biomedicines10081795
  2. Dai R, Wu M, Zhang Y et al. (2021) G protein nucleolar 3 promotes non-Hodgkin lymphoma progression by activating the Wnt/beta-catenin signaling pathway. Exp Cell Res 409:112911. https://doi.org/10.1016/j.yexcr.2021.112911
  3. De Souza LM, Ismail M, Elaskandrany MA et al. (2024) Primary hepatic EBV-DLBCL lymphoma in the setting of COVID-19 infection. ACG Case Rep J 11:e01276. https://doi.org/10.14309/crj.0000000000001276
  4. Du X, Zhang M, Wang S et al. (2024) Ethnopharmacology, chemical composition and functions of Cymbopogon citratus. Chin Herb Med 16:358–374. https://doi.org/10.1016/j.chmed.2023.07.002
  5. Huang LJ, Lan JX, Wang JH et al. (2024) Bioactivity and mechanism of action of sanguinarine and its derivatives in the past 10 years. Biomed Pharmacother 173:116406. https://doi.org/10.1016/j.biopha.2024.116406
  6. Hu M, Trevino J, Yang L et al. (2018) Primary gastric EBV-positive diffuse large B cell lymphoma (DLBCL) of the elderly with plasmablastic differentiation. In Vivo 32:413–417. https://doi.org/10.21873/invivo.11255
  7. Liu P, Zhao M, Lin Y et al. (2023) Platycodin D induces proliferation inhibition and mitochondrial apoptosis in diffuse large B-cell lymphoma. Exp Hematol 123:46–55. https://doi.org/10.1016/j.exphem.2023.04.002
  8. Lu K, Li B, Zhang H et al. (2020) A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathway. Signal Transduct Target Ther 5:31. https://doi.org/10.1038/s41392-020-0123-0
  9. Narita K, Takeuchi K (2023) FISH for EBV genome in a patient with diffuse large B-cell lymphoma harboring t(14;18)(q32;q21). Blood 142:1172. https://doi.org/10.1182/blood.2023021546
  10. Ohashi A, Kato S, Okamoto A et al. (2017) Reappraisal of Epstein–Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells. Histopathology 71:89–97. https://doi.org/10.1111/his.13197
  11. Pallichankandy S, Thayyullathil F, Cheratta AR et al. (2023) Targeting oxeiptosis-mediated tumor suppression: a novel approach to treat colorectal cancers by sanguinarine. Cell Death Discov 9:94. https://doi.org/10.1038/s41420-023-01376-3
  12. Prabhu KS, Bhat AA, Siveen KS et al. (2021) Sanguinarine mediated apoptosis in non-small cell lung cancer via generation of reactive oxygen species and suppression of JAK/STAT pathway. Biomed Pharmacother 144:112358. https://doi.org/10.1016/j.biopha.2021.112358
  13. Qi X, Chen Y, Liu S et al. (2023) Sanguinarine inhibits melanoma invasion and migration by targeting the FAK/PI3K/AKT/mTOR signalling pathway. Pharm Biol 61:696–709. https://doi.org/10.1080/13880209.2023.2200787
  14. Qin TT, Li ZH, Li LX et al. (2022) Sanguinarine, identified as a natural alkaloid LSD1 inhibitor, suppresses lung cancer cell growth and migration. Iran J Basic Med Sci 25:781–788. https://doi.org/10.22038/IJBMS.2022.62541.13851
  15. Ren K, Pei J, Guo Y et al. (2023) Regulated necrosis pathways: a potential target for ischemic stroke. Burns Trauma 11:tkad016. https://doi.org/10.1093/burnst/tkad016
  16. Seog W, Tae K, Kim M, Cho S-G et al. (2025) Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.[J]. Nat Cancer. Doi: 10.1038/s43018-025-00921-6
  17. Shold J, Jukic L, Farrell D et al. (2024) EBV positive diffuse large B cell lymphoma with negative Pan-B cell markers, case report, and literature review. Case Rep Hematol 2024:4803071. https://doi.org/10.1155/2024/4803071
  18. Tang D, Su W, Wang X et al. (2021) Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas. Brain Tumor Pathol 38:50–58. https://doi.org/10.1007/s10014-020-00386-8
  19. Xing X, Liu M, Wang X et al. (2023) FKBP3 aggravates the malignant phenotype of diffuse large B-cell lymphoma by PARK7-mediated activation of Wnt/β-catenin signalling.[J]. J Cell Mol Med 28(1):e18041.
  20. Xing X, Liu M, Wang X et al. (2024) FKBP3 aggravates the malignant phenotype of diffuse large B-cell lymphoma by PARK7-mediated activation of Wnt/beta-catenin signalling. J Cell Mol Med 28:e18041. https://doi.org/10.1111/jcmm.18041
  21. Yang Y, Liu D, Wang Y (2023) Physalin A exerts neuroprotective effects: inhibition of OGD/R-induced cellular pyroptosis and inflammatory responses in nerve cells. Signa Vitae 19:168–174. https://doi.org/10.22514/sv.2023.111
  22. Zhan Y, Teruya-Feldstein J (2019) Immune dysregulation: EBV(+) DLBCL and HLH in a patient with T-LGL. Blood 133:1695. https://doi.org/10.1182/blood-2019-01-899484
  23. Zhang Q, Lai J, Ai S et al. (2024) A case report of surgery-radiotherapy-chemotherapy cured primary diffuse large B-cell lymphoma of the central nervous system associated with HIV infection.[J]. Diagn Pathol 19(1):153.
Language: English
Submitted on: Oct 22, 2024
Accepted on: Jan 14, 2025
Published on: Apr 9, 2025
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2025 Suli Lu, Dae-jung Yang, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.